Bristol-Myers Squibb is spending $74 billion on fellow drugmaker Celgene in a deal aimed at stocking the combined company's development pipeline with cancer, immunology and cardiovascular treatments.
Bristol would gain the cancer treatment Revlimid in the cash-and-stock deal announced Thursday,...
from Home - Chicago Tribune https://trib.in/2Vl9asK
via Chicago Tribune
Labels: Home - Chicago Tribune, IFTTT
Anda baru saja membaca artikel Drug company deal: Bristol-Myers Squibb buying Celgene for $74 billion. Silakan share artikel ini ke media sosial anda.
0 Komentar untuk "Drug company deal: Bristol-Myers Squibb buying Celgene for $74 billion"